Sjogren Syndrome Indication Strategy Report 2026: BAFF, CD40L, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Systemic Lupus Erythematosus Indication Strategy Report 2026: BAFF, CD19, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Rheumatoid Arthritis Indication Strategy Report 2026: TNF, JAK1, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Psoriatic Arthritis Indication Strategy Report 2026: IL-17, TYK2, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Plaque Psoriasis Indication Strategy Report 2026: IL-17, IL-23, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Crohn Disease Indication Strategy Report 2026: TNF, IL-23, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Ulcerative Colitis Indication Strategy Report 2026: IL-23, JAK1, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Waldenstrom Macroglobulinemia Indication Strategy Report 2026: BTK, CXCR4, Trials and Deals uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Uveal Melanoma Indication Strategy Report 2026: GNAQ, PKC, Trials and Deal Outlook uses PatSnap MCP evidence to evaluate disease burden, target rationale, clinical competition, transaction signals, unmet need and market attractiveness for one indication only.

Agenus 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

Y-mAbs Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.

TScan Therapeutics 2026 BD opportunity scan: pipeline assets, transaction precedents, financial signals, IP-risk flags, and a prioritized partnering shortlist.